<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048667</url>
  </required_header>
  <id_info>
    <org_study_id>20210887</org_study_id>
    <nct_id>NCT05048667</nct_id>
  </id_info>
  <brief_title>Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction</brief_title>
  <acronym>COCKTAIL</acronym>
  <official_title>Novel Treatment for Microvascular Erectile Dysfunction Combining Shockwave Therapy and Platelet Rich Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate whether the combination of Shock Wave&#xD;
      Therapy (SWT) with Platelet Rich Plasma (PRP) is synergistic and can reverse the pathology of&#xD;
      microvascular Erectile Dysfunction (ED) and enhance erectile function by improving&#xD;
      vasodilation, and endothelial function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">December 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IIEF-EF Scores</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>International Index of Erectile Function - Erectile Function Subdomain Score (IIEF-EF) is a 5-item subdomain self- evaluation questionnaire of erectile function with a total score ranging from 0-25 with the higher score indicating better erectile function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving MCID in IIEF-EF</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>IIEF-EF is a 5-item subdomain self- evaluation questionnaire of erectile function with a total score ranging from 0-25 with the higher score indicating better erectile function. Mild Clinically Important Difference (MCID) is attained via an increase of 2 points in IIEF-EF score for participants with mild ED and an increase of 5 points for participants with moderate ED.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penile Blood Flow</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Penile Blood Flow will be reported as Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV), both assessed in cm/sec, via Penile Doppler ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EPC-CFU levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Endothelial function reported as the Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating Angiogenic Factor levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Circulating angiogenic factor levels including Vascular Endothelial Growth Factor (VEGF), Stromal Cell Derived Factor-1 (SDF-1 alpha) and Stem cell Factor (SCF), all reported in pg/mL, will be assessed via blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penile Flow Mediated Dilation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Penile Flow Mediated Dilation will be assessed using Penile Doppler ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting a decrease or discontinue in use of PDE5 inhibitors</measure>
    <time_frame>6 months</time_frame>
    <description>The number of participants reporting a decrease or discontinue in use of PDE5 inhibitors will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>SWT plus PRP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive weekly Shock Wave Therapy (SWT) and Platelet Rich Plasma (PRP) for 4 weeks. SWT will be administered weekly on Day 1 and Weeks 1, 2, 3 and 4. PRP will be administered on Day 1 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham SWT plus Placebo Saline Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive weekly Sham Shock Wave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 4 weeks. Sham SWT will be administered weekly on Day 1 and Weeks 1, 2, 3 and 4. Placebo Saline ICI will be administered on Day 1 and Week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shock Wave therapy (SWT)</intervention_name>
    <description>Each SWT will administer 720 shocks in the treatment arm.</description>
    <arm_group_label>SWT plus PRP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet Rich Plasma (PRP)</intervention_name>
    <description>5 mL PRP will be administered via intracavernous injection</description>
    <arm_group_label>SWT plus PRP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham SWT</intervention_name>
    <description>Sham SWT will be administered in the treatment arm</description>
    <arm_group_label>Sham SWT plus Placebo Saline Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Saline</intervention_name>
    <description>5 mL Placebo saline will be administered via intracavernous injection</description>
    <arm_group_label>Sham SWT plus Placebo Saline Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be Male&#xD;
&#xD;
          2. Be 30 to 80 years of age (inclusive).&#xD;
&#xD;
          3. Be able to provide written informed consent.&#xD;
&#xD;
          4. Have a diagnosis of ED due to organic origin for at least 6 months prior to consent.&#xD;
&#xD;
          5. Sexually active in a stable, heterosexual relationship of more than three months&#xD;
             duration.&#xD;
&#xD;
          6. IIEF-EF score 12-25 at screening&#xD;
&#xD;
          7. Agree to attempt sexual intercourse at least 4 times per month for the duration of the&#xD;
             study without being under the influence of alcohol or recreational drugs.&#xD;
&#xD;
          8. Agree to comply with all study related tests/procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous penile surgery of any kind (except circumcision and condyloma removal), such&#xD;
             as penile lengthening, penile cancer surgery, penile plication, grafting.&#xD;
&#xD;
          2. Previous history of priapism or penile fracture&#xD;
&#xD;
          3. Abnormal morning serum testosterone level defined as a value lower than 300 ng/dL&#xD;
             (±5%) (indicative of untreated hypogonadism), or greater than 1197 ng/dL (±5%).&#xD;
&#xD;
          4. Current or previous hormone usage, other than prescribed testosterone, clomiphene or&#xD;
             thyroid medication. (Subjects with prior or current use of hormonal treatment for&#xD;
             prostate cancer are also excluded.&#xD;
&#xD;
          5. Psychogenic ED as determined by study investigator.&#xD;
&#xD;
          6. Anatomical (Peyronie's Disease or penile curvature that negatively influences sexual&#xD;
             activity) or neurological abnormalities in the treatment area.&#xD;
&#xD;
          7. Patients using Intracavernosal Injection (ICI) for management of ED&#xD;
&#xD;
          8. Patients with generalized polyneuropathy, or neurological conditions irrespective of&#xD;
             cause, such as severe diabetes, multiple sclerosis or Parkinson's disease.&#xD;
&#xD;
          9. Have a serious comorbid illness/condition/behavior that, in the opinion of the&#xD;
             investigator, may compromise the safety or compliance of the subject or preclude&#xD;
             successful completion of the study.&#xD;
&#xD;
         10. History of consistent treatment failure with Phosphodiesterase Type 5 (PDE5)&#xD;
             inhibitors for therapy of ED.&#xD;
&#xD;
         11. Any history of significant psychiatric disease, such as bipolar disorder or psychosis,&#xD;
             greater than one lifetime episode of major depression, current depression of moderate&#xD;
             or greater severity. Patients who are currently using Selective Serotonin Reuptake&#xD;
             Inhibitors (SSRI) or psychotropic medications.&#xD;
&#xD;
         12. Hemoglobin a1c &gt;9%.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Molina, MD</last_name>
    <phone>305-243-4873</phone>
    <email>m.molina.leyba@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ranjith Ramasamy, MD</last_name>
      <phone>305-243-4562</phone>
      <email>ramasamy@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjith Ramasamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013 Dec;9(12):721-30. doi: 10.1038/nrrheum.2013.141. Epub 2013 Oct 1. Review.</citation>
    <PMID>24080861</PMID>
  </reference>
  <reference>
    <citation>Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008 Dec;1(3-4):165-74. doi: 10.1007/s12178-008-9032-5.</citation>
    <PMID>19468902</PMID>
  </reference>
  <reference>
    <citation>Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014 Feb 25;16(1):204. Review.</citation>
    <PMID>25164150</PMID>
  </reference>
  <reference>
    <citation>Randelli P, Randelli F, Ragone V, Menon A, D'Ambrosi R, Cucchi D, Cabitza P, Banfi G. Regenerative medicine in rotator cuff injuries. Biomed Res Int. 2014;2014:129515. doi: 10.1155/2014/129515. Epub 2014 Aug 13. Review.</citation>
    <PMID>25184132</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Rokkas K, Ioakeimidis N, Aggeli C, Michaelides A, Roussakis G, Fassoulakis C, Askitis A, Stefanadis C. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol. 2005 Dec;48(6):996-1002; discussion 1002-3. Epub 2005 Aug 24.</citation>
    <PMID>16174548</PMID>
  </reference>
  <reference>
    <citation>Haupt G, Haupt A, Ekkernkamp A, Gerety B, Chvapil M. Influence of shock waves on fracture healing. Urology. 1992 Jun;39(6):529-32.</citation>
    <PMID>1615601</PMID>
  </reference>
  <reference>
    <citation>Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999 Jan;161(1):5-11. Review.</citation>
    <PMID>10037356</PMID>
  </reference>
  <reference>
    <citation>Kikuchi Y, Ito K, Ito Y, Shiroto T, Tsuburaya R, Aizawa K, Hao K, Fukumoto Y, Takahashi J, Takeda M, Nakayama M, Yasuda S, Kuriyama S, Tsuji I, Shimokawa H. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J. 2010 Mar;74(3):589-91. Epub 2010 Feb 4.</citation>
    <PMID>20134096</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ranjith Ramasamy, MD</investigator_full_name>
    <investigator_title>Associate Professor of Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

